tradingkey.logo

Quantum BioPharma Ltd

QNTM
8.890USD
+0.070+0.79%
收盤 12/19, 16:00美東報價延遲15分鐘
33.93M總市值
虧損本益比TTM

Quantum BioPharma Ltd

8.890
+0.070+0.79%

關於 Quantum BioPharma Ltd 公司

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Quantum BioPharma Ltd簡介

公司代碼QNTM
公司名稱Quantum BioPharma Ltd
上市日期May 29, 2018
CEOKotra (Lakshmi P)
員工數量- -
證券類型Ordinary Share
年結日May 29
公司地址55 University Ave. , Suite 1003
城市TORONTO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編M5J 2H7
電話14168548884
網址https://www.quantumbiopharma.com/
公司代碼QNTM
上市日期May 29, 2018
CEOKotra (Lakshmi P)

Quantum BioPharma Ltd公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-72.73%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Kevin Cassidy
Mr. Kevin Cassidy
Vice President - Quality of Lucid
Vice President - Quality of Lucid
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-100.00%
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-72.73%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月2日 週二
更新時間: 12月2日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Malone Wealth Ventures LLC
27.43%
Saeed (Zeeshan)
3.10%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
AdvisorShares Investments, LLC
0.98%
其他
64.77%
持股股東
持股股東
佔比
Malone Wealth Ventures LLC
27.43%
Saeed (Zeeshan)
3.10%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
AdvisorShares Investments, LLC
0.98%
其他
64.77%
股東類型
持股股東
佔比
Investment Advisor
29.12%
Individual Investor
8.54%
Investment Advisor/Hedge Fund
1.36%
Corporation
0.37%
Research Firm
0.09%
其他
60.52%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
40
1.17M
30.70%
+254.90K
2025Q2
50
1.04M
35.99%
+612.85K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
2023Q3
52
164.58K
27.23%
+48.13K
2023Q2
52
164.21K
27.10%
+38.85K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Malone Wealth Ventures LLC
1.05M
27.43%
+217.43K
+26.20%
Sep 06, 2025
Saeed (Zeeshan)
118.41K
3.1%
+300.00
+0.25%
Aug 14, 2025
Carroll (Donal)
90.41K
2.37%
+7.69K
+9.30%
Apr 03, 2025
Lynch (Terrence)
51.42K
1.35%
+51.42K
--
Aug 14, 2025
AdvisorShares Investments, LLC
36.99K
0.97%
-12.00K
-24.49%
Jun 30, 2025
Kotra (Lakshmi)
29.57K
0.77%
--
--
Aug 14, 2025
Durkacz (Anthony)
106.76K
2.8%
--
--
Aug 14, 2025
UBS Financial Services, Inc.
45.88K
1.2%
+44.27K
+2742.81%
Jun 30, 2025
Saeed (Rehan)
6.79K
0.18%
-2.15K
-24.09%
Dec 31, 2024
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
AdvisorShares Psychedelics ETF
6.05%
AdvisorShares Psychedelics ETF
佔比6.05%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
公告日期
類型
比率
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1

常見問題

Quantum BioPharma Ltd的前五大股東是誰?

Quantum BioPharma Ltd的前五大股東如下:
Malone Wealth Ventures LLC
持有股份:1.05M
佔總股份比例:27.43%。
Saeed (Zeeshan)
持有股份:118.41K
佔總股份比例:3.10%。
Carroll (Donal)
持有股份:90.41K
佔總股份比例:2.37%。
Lynch (Terrence)
持有股份:51.42K
佔總股份比例:1.35%。
AdvisorShares Investments, LLC
持有股份:36.99K
佔總股份比例:0.97%。

Quantum BioPharma Ltd的前三大股東類型是什麼?

Quantum BioPharma Ltd 的前三大股東類型分別是:
Malone Wealth Ventures LLC
Saeed (Zeeshan)
Carroll (Donal)

有多少機構持有Quantum BioPharma Ltd(QNTM)的股份?

截至2025Q3,共有40家機構持有Quantum BioPharma Ltd的股份,合計持有的股份價值約為1.17M,占公司總股份的30.70% 。與2025Q2相比,機構持股有所增加,增幅為-5.29%。

哪個業務部門對Quantum BioPharma Ltd的收入貢獻最大?

在--,--業務部門對Quantum BioPharma Ltd的收入貢獻最大,創收--,占總收入的--% 。
KeyAI